Liquidia/LQDA

$14.13

-3.15%
-
1D1W1MYTD1YMAX

About Liquidia

Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture, and commercialization of products that address unmet patient needs, with a focus on the treatment of pulmonary hypertension (PH). The Company operates, through its wholly owned subsidiaries, Liquidia Technologies, Inc., and Liquidia PAH, LLC. It conducts research, development, and manufacturing of products by applying its expertise in cardiopulmonary diseases and its PRINT technology, a particle engineering platform that enables the production of uniform drug particles designed to improve the safety, efficacy, and performance of a range of therapies. Its lead product candidate is YUTREPIA for the treatment of pulmonary arterial hypertension (PAH). YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low resistance dry-powder inhaler (DPI).
Ticker
LQDA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Roger Jeffs
Employees
59
Headquarters
Morrisville, United States

Liquidia Metrics

BasicAdvanced
$1B
Market cap
-
P/E ratio
-$0.89
EPS
0.14
Beta
-
Dividend rate

What the Analysts think about Liquidia

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
47.63% upside
High $30.00
Low $3.00
$14.13
Current price
$20.86
Average price target

Liquidia Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-436.11% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3.6M
-23.4%
Net income
$-15.7M
-33.19%
Profit margin
-436.11%
-12.78%

Liquidia Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 12.07%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.09
-$0.18
-$0.36
-$0.24
-
Expected
-$0.16
-$0.16
-$0.16
-$0.21
-$0.24
Surprise
-41.94%
10.92%
120.47%
12.07%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Liquidia stock

Buy or sell Liquidia stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing